Flibanserin (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Flibanserin" in Italian language version.

refsWebsite

Global rank Italian rank

13nih.gov

4^th place

9^th place

12doi.org

2^nd place

7^th place

10oadoi.org

799^th place

22^nd place

3worldcat.org

5^th place

26^th place

3unibo.it

4,963^rd place

325^th place

2news-medical.net

8,069^th place

6,596^th place

2fda.gov

447^th place

644^th place

2wiley.com

222^nd place

243^rd place

1rainews.it

1,908^th place

78^th place

1adnkronos.com

1,287^th place

47^th place

1nature.com

234^th place

226^th place

1cnn.com

28^th place

84^th place

1theguardian.com

12^th place

32^nd place

1scientificamerican.com

896^th place

1,590^th place

1nytimes.com

7^th place

19^th place

1archive.org

6^th place

8^th place

1books.google.com

3^rd place

14^th place

adnkronos.com

Farmaceutica: da Valeant 1 mld di dollari per 'viagra rosa', la voce degli analisti - Adnkronos, su adnkronos.com, 21 agosto 2015.

archive.org

Roberto William Invernizzi, Giuseppina Sacchetti, Stefania Parini, Sabrina Acconcia e Rosario Samanin, Flibanserin, a potential antidepressant drug, lowers 5-HT and raises dopamine and noradrenaline in the rat prefrontal cortex dialysate: role of 5-HT1Areceptors, in British Journal of Pharmacology, vol. 139, n. 7, 2003, pp. 1281–1288, DOI:10.1038/sj.bjp.0705341, ISSN 0007-1188 (WC · ACNP).

books.google.com

Stephen M. Stahl e S. M. Stahl, Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications, Cambridge University Press, 17 marzo 2008, p. 658, ISBN 978-0-521-67376-1. URL consultato il 23 aprile 2012.

cnn.com

FDA: Female sex drive drug needs more research - CNN.com

doi.org

dx.doi.org

Stahl SM, Mechanism of action of flibanserin, a multifunctional serotonin agonist and antagonist (MSAA), in hypoactive sexual desire disorder, in CNS Spectr, vol. 20, n. 1, 2015, pp. 1–6, DOI:10.1017/S1092852914000832, PMID 25659981.
D'Aquila P, Monleon S, Borsini F, Brain P, Willner P, Anti-anhedonic actions of the novel serotonergic agent flibanserin, a potential rapidly-acting antidepressant, in European Journal of Pharmacology, vol. 340, 2–3, December 1997, pp. 121–32, DOI:10.1016/S0014-2999(97)01412-X, PMID 9537806.
Invernizzi RW, Sacchetti G, Parini S, Acconcia S, Samanin R, Flibanserin, a potential antidepressant drug, lowers 5-HT and raises dopamine and noradrenaline in the rat prefrontal cortex dialysate: role of 5-HT1A receptors, in Br J Pharmacol., vol. 139, n. 7, August 2003, pp. 1281–8, DOI:10.1038/sj.bjp.0705341, PMC 1573953, PMID 12890707.
Simon JA, Kingsberg SA, Shumel B, Hanes V, Garcia M, Sand M, Efficacy and safety of flibanserin in postmenopausal women with hypoactive sexual desire disorder: results of the SNOWDROP trial, in Menopause, vol. 21, n. 6, 2014, pp. 633–40, DOI:10.1097/GME.0000000000000134, PMID 24281236.
Gellad WF, Flynn KE, Alexander GC, Evaluation of Flibanserin: Science and Advocacy at the FDA, in JAMA, 2015, DOI:10.1001/jama.2015.8405, PMID 26148201.
Nappi RE, Why are there no FDA-approved treatments for female sexual dysfunction?, in Expert Opin Pharmacother, vol. 16, n. 12, 2015, pp. 1735–8, DOI:10.1517/14656566.2015.1064393, PMID 26165387.
Meixel A, Yanchar E, Fugh-Berman A, Hypoactive sexual desire disorder: inventing a disease to sell low libido, in J Med Ethics, 2015, DOI:10.1136/medethics-2014-102596, PMID 26124287.
Roberto William Invernizzi, Giuseppina Sacchetti, Stefania Parini, Sabrina Acconcia e Rosario Samanin, Flibanserin, a potential antidepressant drug, lowers 5-HT and raises dopamine and noradrenaline in the rat prefrontal cortex dialysate: role of 5-HT1Areceptors, in British Journal of Pharmacology, vol. 139, n. 7, 2003, pp. 1281–1288, DOI:10.1038/sj.bjp.0705341, ISSN 0007-1188 (WC · ACNP).
Stephen M. Stahl, Mechanism of action of flibanserin, a multifunctional serotonin agonist and antagonist (MSAA), in hypoactive sexual desire disorder, in CNS Spectrums, vol. 20, n. 01, 2015, pp. 1–6, DOI:10.1017/S1092852914000832, ISSN 1092-8529 (WC · ACNP).
Stephen M. Stahl, Bernd Sommer e Kelly A. Allers, Multifunctional Pharmacology of Flibanserin: Possible Mechanism of Therapeutic Action in Hypoactive Sexual Desire Disorder, in The Journal of Sexual Medicine, vol. 8, n. 1, 2011, pp. 15–27, DOI:10.1111/j.1743-6109.2010.02032.x, ISSN 1743-6095 (WC · ACNP).
Scandroglio A, Monferini E, Borsini F, Ex vivo binding of flibanserin to serotonin 5-HT1A and 5-HT2A receptors, in Pharmacol. Res., vol. 43, n. 2, 2001, pp. 179–83, DOI:10.1006/phrs.2000.0762, PMID 11243720.
Stahl SM, Sommer B, Allers KA, Multifunctional pharmacology of flibanserin: possible mechanism of therapeutic action in hypoactive sexual desire disorder, in J Sex Med, vol. 8, n. 1, 2011, pp. 15–27, DOI:10.1111/j.1743-6109.2010.02032.x, PMID 20840530.

fda.gov

nature.com

Invernizzi RW, Sacchetti G, Parini S, Acconcia S, Samanin R, Flibanserin, a potential antidepressant drug, lowers 5-HT and raises dopamine and noradrenaline in the rat prefrontal cortex dialysate: role of 5-HT1A receptors, in Br J Pharmacol., vol. 139, n. 7, August 2003, pp. 1281–8, DOI:10.1038/sj.bjp.0705341, PMC 1573953, PMID 12890707.

news-medical.net

Sprout Pharmaceuticals resubmits flibanserin NDA for treating HSDD in pre-menopausal women, 27 giugno 2013.
(EN) Sprout Pharmaceuticals resubmits flibanserin NDA for treating HSDD in pre-menopausal women, su news-medical.net, 27 giugno 2013.

nih.gov

ncbi.nlm.nih.gov

Stahl SM, Mechanism of action of flibanserin, a multifunctional serotonin agonist and antagonist (MSAA), in hypoactive sexual desire disorder, in CNS Spectr, vol. 20, n. 1, 2015, pp. 1–6, DOI:10.1017/S1092852914000832, PMID 25659981.
D'Aquila P, Monleon S, Borsini F, Brain P, Willner P, Anti-anhedonic actions of the novel serotonergic agent flibanserin, a potential rapidly-acting antidepressant, in European Journal of Pharmacology, vol. 340, 2–3, December 1997, pp. 121–32, DOI:10.1016/S0014-2999(97)01412-X, PMID 9537806.
Invernizzi RW, Sacchetti G, Parini S, Acconcia S, Samanin R, Flibanserin, a potential antidepressant drug, lowers 5-HT and raises dopamine and noradrenaline in the rat prefrontal cortex dialysate: role of 5-HT1A receptors, in Br J Pharmacol., vol. 139, n. 7, August 2003, pp. 1281–8, DOI:10.1038/sj.bjp.0705341, PMC 1573953, PMID 12890707.
Simon JA, Kingsberg SA, Shumel B, Hanes V, Garcia M, Sand M, Efficacy and safety of flibanserin in postmenopausal women with hypoactive sexual desire disorder: results of the SNOWDROP trial, in Menopause, vol. 21, n. 6, 2014, pp. 633–40, DOI:10.1097/GME.0000000000000134, PMID 24281236.
Zeman FJ, Heng H, Hoogenboom ER, Kavlock RJ, Mahboob S, Cell number and size in selected organs of fetuses of rats malnourished and exposed to nitrofen, in Teratog., Carcinog. Mutagen., vol. 6, n. 4, 1986, pp. 339–47, PMID 2428123.
Gellad WF, Flynn KE, Alexander GC, Evaluation of Flibanserin: Science and Advocacy at the FDA, in JAMA, 2015, DOI:10.1001/jama.2015.8405, PMID 26148201.
Nappi RE, Why are there no FDA-approved treatments for female sexual dysfunction?, in Expert Opin Pharmacother, vol. 16, n. 12, 2015, pp. 1735–8, DOI:10.1517/14656566.2015.1064393, PMID 26165387.
Meixel A, Yanchar E, Fugh-Berman A, Hypoactive sexual desire disorder: inventing a disease to sell low libido, in J Med Ethics, 2015, DOI:10.1136/medethics-2014-102596, PMID 26124287.
Borsini F, Evans K, Jason K, Rohde F, Alexander B, Pollentier S, Pharmacology of flibanserin, in CNS Drug Rev, vol. 8, n. 2, 2002, pp. 117–42, PMID 12177684.
Borsini F, Giraldo E, Monferini E, Antonini G, Parenti M, Bietti G, Donetti A, BIMT 17, a 5-HT2A receptor antagonist and 5-HT1A receptor full agonist in rat cerebral cortex, in Naunyn Schmiedebergs Arch. Pharmacol., vol. 352, n. 3, 1995, pp. 276–82, PMID 8584042.
Borsini F, Evans K, Jason K, Rohde F, Alexander B, Pollentier S, Pharmacology of flibanserin, in CNS Drug Rev, vol. 8, n. 2, 2002, pp. 117–42, PMID 12177684.
Scandroglio A, Monferini E, Borsini F, Ex vivo binding of flibanserin to serotonin 5-HT1A and 5-HT2A receptors, in Pharmacol. Res., vol. 43, n. 2, 2001, pp. 179–83, DOI:10.1006/phrs.2000.0762, PMID 11243720.
Stahl SM, Sommer B, Allers KA, Multifunctional pharmacology of flibanserin: possible mechanism of therapeutic action in hypoactive sexual desire disorder, in J Sex Med, vol. 8, n. 1, 2011, pp. 15–27, DOI:10.1111/j.1743-6109.2010.02032.x, PMID 20840530.

nytimes.com

F.D.A. Approves Addyi, a Libido Pill for Women, su nytimes.com.

oadoi.org

Stahl SM, Mechanism of action of flibanserin, a multifunctional serotonin agonist and antagonist (MSAA), in hypoactive sexual desire disorder, in CNS Spectr, vol. 20, n. 1, 2015, pp. 1–6, DOI:10.1017/S1092852914000832, PMID 25659981.
D'Aquila P, Monleon S, Borsini F, Brain P, Willner P, Anti-anhedonic actions of the novel serotonergic agent flibanserin, a potential rapidly-acting antidepressant, in European Journal of Pharmacology, vol. 340, 2–3, December 1997, pp. 121–32, DOI:10.1016/S0014-2999(97)01412-X, PMID 9537806.
Simon JA, Kingsberg SA, Shumel B, Hanes V, Garcia M, Sand M, Efficacy and safety of flibanserin in postmenopausal women with hypoactive sexual desire disorder: results of the SNOWDROP trial, in Menopause, vol. 21, n. 6, 2014, pp. 633–40, DOI:10.1097/GME.0000000000000134, PMID 24281236.
Gellad WF, Flynn KE, Alexander GC, Evaluation of Flibanserin: Science and Advocacy at the FDA, in JAMA, 2015, DOI:10.1001/jama.2015.8405, PMID 26148201.
Nappi RE, Why are there no FDA-approved treatments for female sexual dysfunction?, in Expert Opin Pharmacother, vol. 16, n. 12, 2015, pp. 1735–8, DOI:10.1517/14656566.2015.1064393, PMID 26165387.
Meixel A, Yanchar E, Fugh-Berman A, Hypoactive sexual desire disorder: inventing a disease to sell low libido, in J Med Ethics, 2015, DOI:10.1136/medethics-2014-102596, PMID 26124287.
Stephen M. Stahl, Mechanism of action of flibanserin, a multifunctional serotonin agonist and antagonist (MSAA), in hypoactive sexual desire disorder, in CNS Spectrums, vol. 20, n. 01, 2015, pp. 1–6, DOI:10.1017/S1092852914000832, ISSN 1092-8529 (WC · ACNP).
Stephen M. Stahl, Bernd Sommer e Kelly A. Allers, Multifunctional Pharmacology of Flibanserin: Possible Mechanism of Therapeutic Action in Hypoactive Sexual Desire Disorder, in The Journal of Sexual Medicine, vol. 8, n. 1, 2011, pp. 15–27, DOI:10.1111/j.1743-6109.2010.02032.x, ISSN 1743-6095 (WC · ACNP).
Scandroglio A, Monferini E, Borsini F, Ex vivo binding of flibanserin to serotonin 5-HT1A and 5-HT2A receptors, in Pharmacol. Res., vol. 43, n. 2, 2001, pp. 179–83, DOI:10.1006/phrs.2000.0762, PMID 11243720.
Stahl SM, Sommer B, Allers KA, Multifunctional pharmacology of flibanserin: possible mechanism of therapeutic action in hypoactive sexual desire disorder, in J Sex Med, vol. 8, n. 1, 2011, pp. 15–27, DOI:10.1111/j.1743-6109.2010.02032.x, PMID 20840530.

rainews.it

Usa: via libera ad Addyi, primo medicinale che potenzia la libido delle donne - Rai News, su rainews.it, Rai News, 20 agosto 2015.

scientificamerican.com

The Myth of "Female Viagra", su scientificamerican.com.

theguardian.com

Jana Kasperkevic, FDA approves 'female Viagra' pill Flibanserin after two rejections, su The Guardian. URL consultato il 18 agosto 2015.

unibo.it

acnpsearch.unibo.it

Roberto William Invernizzi, Giuseppina Sacchetti, Stefania Parini, Sabrina Acconcia e Rosario Samanin, Flibanserin, a potential antidepressant drug, lowers 5-HT and raises dopamine and noradrenaline in the rat prefrontal cortex dialysate: role of 5-HT1Areceptors, in British Journal of Pharmacology, vol. 139, n. 7, 2003, pp. 1281–1288, DOI:10.1038/sj.bjp.0705341, ISSN 0007-1188 (WC · ACNP).
Stephen M. Stahl, Mechanism of action of flibanserin, a multifunctional serotonin agonist and antagonist (MSAA), in hypoactive sexual desire disorder, in CNS Spectrums, vol. 20, n. 01, 2015, pp. 1–6, DOI:10.1017/S1092852914000832, ISSN 1092-8529 (WC · ACNP).
Stephen M. Stahl, Bernd Sommer e Kelly A. Allers, Multifunctional Pharmacology of Flibanserin: Possible Mechanism of Therapeutic Action in Hypoactive Sexual Desire Disorder, in The Journal of Sexual Medicine, vol. 8, n. 1, 2011, pp. 15–27, DOI:10.1111/j.1743-6109.2010.02032.x, ISSN 1743-6095 (WC · ACNP).

wiley.com

onlinelibrary.wiley.com

Borsini F, Evans K, Jason K, Rohde F, Alexander B, Pollentier S, Pharmacology of flibanserin, in CNS Drug Rev, vol. 8, n. 2, 2002, pp. 117–42, PMID 12177684.
(EN) Stephen M. Stahl MD, Bernd Sommer PhD and Kelly A. Allers PhD,, Multifunctional Pharmacology of Flibanserin: Possible Mechanism of Therapeutic Action in Hypoactive Sexual Desire Disorder - Stahl - 2010 - The Journal of Sexual Medicine - Wiley Online Library, su onlinelibrary.wiley.com, The Journal of Sexual Medicine - Wiley Online Library. URL consultato il 20 agosto 2015.

worldcat.org

Roberto William Invernizzi, Giuseppina Sacchetti, Stefania Parini, Sabrina Acconcia e Rosario Samanin, Flibanserin, a potential antidepressant drug, lowers 5-HT and raises dopamine and noradrenaline in the rat prefrontal cortex dialysate: role of 5-HT1Areceptors, in British Journal of Pharmacology, vol. 139, n. 7, 2003, pp. 1281–1288, DOI:10.1038/sj.bjp.0705341, ISSN 0007-1188 (WC · ACNP).
Stephen M. Stahl, Mechanism of action of flibanserin, a multifunctional serotonin agonist and antagonist (MSAA), in hypoactive sexual desire disorder, in CNS Spectrums, vol. 20, n. 01, 2015, pp. 1–6, DOI:10.1017/S1092852914000832, ISSN 1092-8529 (WC · ACNP).
Stephen M. Stahl, Bernd Sommer e Kelly A. Allers, Multifunctional Pharmacology of Flibanserin: Possible Mechanism of Therapeutic Action in Hypoactive Sexual Desire Disorder, in The Journal of Sexual Medicine, vol. 8, n. 1, 2011, pp. 15–27, DOI:10.1111/j.1743-6109.2010.02032.x, ISSN 1743-6095 (WC · ACNP).